Today we reported Q2 2024 financial results. Read more about our updates and tune in live to the webcast today at 11:30 AM ET to hear our second quarter highlights: https://lnkd.in/e5Aeh6kC
About us
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.
- Website
-
http://www.ionis.com
External link for Ionis Pharmaceuticals, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Carlsbad, CA
- Type
- Public Company
- Founded
- 1989
- Specialties
- RNA-targeted medicines and RNA-targeted therapeutics
Locations
-
Primary
2855 Gazelle Ct
Carlsbad, CA 92010, US
Employees at Ionis Pharmaceuticals, Inc.
Updates
-
Today we recognize Disability Independence Day, commemorating the signing of the Americans with Disabilities Act (ADA) over 30 years ago! At Ionis, we continuously strive to gain a deeper understanding of the lived experiences of caregivers and patients with differing abilities, and recently, our Quality Assurance and Manufacturing Operations groups hosted “I AM POSSIBLE,” a teambuilding event with support from members of Adapt Functional Movement Center alongside talented athletes from Challenged Athletes Foundation. Through adaptive experiences including seated volleyball, hand cycling, lift and transfer technique demos, therapeutic massage, live music, and socializing, we raised awareness of these lived experiences amongst our Ions in a fun and safe environment!
-
Today, we shared encouraging results from the HALOS study of our investigational medicine for #AngelmanSyndrome (AS) at the Angelman Syndrome Foundation Family Conference, showing the potentially transformative impact functional improvements could have on people living with AS and their caregivers.
-
-
We're pleased to share positive results from our HALOS study evaluating our investigational medicine for the treatment of #AngelmanSyndrome. Based on these findings, we believe our Angelman program is positioned to become the cornerstone of our wholly owned pipeline for #neurological conditions. Read more: https://lnkd.in/eR352MUJ
-
-
Today we announced positive detailed results from the HALOS study of our investigational medicine for the treatment of #AngelmanSyndrome. Read more: https://lnkd.in/eR352MUJ #RareDisease
-
-
We’re pleased to announce that we have achieved full patient enrollment in the pivotal #clinicaltrial of our investigational medicine for people living with #Alexanderdisease. Read more: https://lnkd.in/e6Z8_b8e
-
-
The U.S. Food and Drug Administration accepted our New Drug Application for the treatment of familial chylomicronemia syndrome (#FCS) and granted Priority Review. In addition, enrollment completed in the Phase 3 severe hypertriglyceridemia (#sHTG) clinical program. Read more: https://lnkd.in/epHKFCF3
-
-
At Ionis, we stand firm in our commitment to steward an inclusive and supportive environment where everyone can thrive. We embrace the authenticity, diversity and unique perspectives of our LGBTQ+ colleagues - during Pride month and throughout the year. By championing these values, we strengthen our teams, drive innovation and build a stronger, more compassionate organization for all. #HappyPride (Video taken June 4th at our flag raising on our Carlsbad campus and followed by a Pride celebration lunch with activities organized by our LGBTQIA+ ERG.)
-
Today, we announced an expanded license agreement with Otsuka Pharmaceutical Co., Ltd. under which Otsuka will support commercialization in Asia Pacific for our investigational prophylactic medicine for hereditary angioedema (#HAE). Read more about this announcement and what it means for people living with this serious #RareDisease: https://lnkd.in/en24U9EJ
-
-
#GlobalFattyLiverDay, led by Global Liver Institute, is an annual moment in time to educate about fatty liver disease, which impacts over 115 million people globally. #FattyLiverDisease may lead to serious complications like cirrhosis, liver cancer or the need for a liver transplant. Due to the lack of obvious symptoms, people impacted by this condition may struggle to receive a diagnosis. Join us in raising awareness of this progressive condition.
-
Similar pages
Browse jobs
Stock
IONS
NASDAQ
20 minutes delay
$47.40
0.4 (0.851%)
- Open
- 46.85
- Low
- 46.36
- High
- 47.58
Data from Refinitiv
See more info on